{"id":"tezepelumab-arm1-arm2","safety":{"commonSideEffects":[{"rate":"5%","effect":"Nasopharyngitis"},{"rate":"4%","effect":"Headache"},{"rate":"3%","effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL3707229","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting TSLP, tezepelumab prevents the activation of immune cells that contribute to the inflammatory response, thereby reducing symptoms associated with allergic diseases such as asthma.","oneSentence":"Tezepelumab blocks the activity of thymic stromal lymphopoietin (TSLP), a key cytokine involved in allergic inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:10.997Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe asthma with an eosinophilic phenotype"},{"name":"Eosinophilic granulomatosis with polyangiitis (EGPA)"}]},"trialDetails":[{"nctId":"NCT07302516","phase":"PHASE3","title":"Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-12-25","conditions":"Asthma","enrollment":636}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"tezepelumab (Arm1&Arm2)","genericName":"tezepelumab (Arm1&Arm2)","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Tezepelumab blocks the activity of thymic stromal lymphopoietin (TSLP), a key cytokine involved in allergic inflammation. Used for Severe asthma with an eosinophilic phenotype, Eosinophilic granulomatosis with polyangiitis (EGPA).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}